Oxford University Press, The Journal of Clinical Endocrinology & Metabolism, 8(94), p. 2792-2798, 2009
DOI: 10.1210/jc.2008-2157
Full text: Download
Context: Thiazolidenediones (TZDs) are selective ligands of peroxisome-proliferator-activated receptor-γ and have been shown to reduce bone mineral density. Recent results from several randomized controlled trials find an increased risk of fracture with TZDs compared with other oral antidiabetic agents.